Is Circular RNA Turning Into The Next Big Thing In R&D?
This year’s American Society of Gene and Cell Therapy congress saw a surge of companies presenting early results on circular RNA platforms – but major challenges remain for the novel technology.
Scrip - May 19, 2026

Cipla Navigates West Asia Strain, Bets On US Momentum
Cipla is cushioning the impact of the Middle East crisis via inventory management and resources on hand and also leaning on momentum in its US business, with products like generic Ventolin lined up for launch, to drive growth.
Generics Bulletin - May 19, 2026

MHRA Addressing Ambiguity Between Wellbeing Apps And Regulated Devices
At RAPS Euro Convergence 2026, the UK regulator discussed its project to remove the ambiguity between wellness apps and regulated devices.
HBW Insight - May 19, 2026

Trump Gx? US President’s Platform Adds Hundreds Of Generics
The recently-launched TrumpRx platform in the US is expanding with the addition of more than 600 generics from firms including Amazon Pharmacy, Mark Cuban’s Cost Plus Drugs, and GoodRx.
Generics Bulletin - May 19, 2026

BioMarin’s BMN 401 Fails To Impress In Phase III ENPP1 Deficiency Study
The mixed results from the Phase III ENERGY 3 trial raises questions around the regulatory path forward for the enzyme therapy.
Scrip - May 19, 2026

Stock Watch: Novo’s Free Pass In A Phony Earnings Season
Novo Nordisk’s first-quarter results drew an initial warm reception, but enthusiasm faded as investors digested a significant one-off windfall, broad-based sales declines in reported currency and the distortion of constant-currency framing.
Scrip - May 19, 2026

Hansa Hails Transformative €115m Idefirix Pact With SERB
Deal Snapshot: With its focus very firmly set on the US, the Swedish biotech has sold the European and MENA rights to the kidney transplant desensitization therapy to the privately -owned Brussels-headquartered company.
Scrip - May 19, 2026

Parexel-Vitrana Deal: The Promise Of AI-Enabled, Single-Partner Pharmacovigilance
Parexel bets on AI-powered pharmacovigilance with the acquisition of Vitrana, whose system-agnostic platform has demonstrated tangible results for existing customers. The deal also gears the CRO for the US FDA's real-time clinical trials push.
Scrip - May 19, 2026

Takeda Reels From $885m Amitiza Reverse-Payment Verdict
Takeda faces more than $2.5bn in potential exposure after a landmark Amitiza pay-for-delay verdict that found its Par settlement delayed generic competition through a non-cash reverse payment and implicit no-AG pact.
Generics Bulletin - May 19, 2026

Biosimilar Streamlining Means All Should ‘Reach The Fruits’
Regulators say comparative efficacy studies will no longer be routine for many biosimilars, but the next phase will test how far the tailored approach can go, and whether markets can keep pace, as discussed at Medicines for Europe’s recent Biosimilar Medicines Conference.
In Vivo - May 19, 2026

Vie Ventures Looks To Fill Autoimmune Disease Funding Gap
Working with disease advocacy groups and wealthy families, Vie will focus on providing funding to help biotechs bridge the gap from candidate nomination to early clinical data.
In Vivo - May 19, 2026

Streamlined Biosimilar Guidelines A Fillip For Hungary’s Richter
Richter says lighter biosimilar trial requirements are improving Biotech prospects, as Q1 delivered a second straight clean EBIT profit on record teriparatide sales, denosumab momentum and new approvals, though steady-state profitability remains a 2027 goal.
Generics Bulletin - May 19, 2026

AstraZeneca Pulls Ahead of Rivals With Baxfendy Approval In Hypertension Battle
Beyond resistant hypertension, AstraZeneca is positioning baxdrostat as a broader CVRM platform asset spanning chronic kidney disease, heart failure and combination strategies with dapagliflozin.
Scrip - May 19, 2026

Europe Cautiously Moves Toward PCCP Implementation
PCCPs are becoming an important part of AI device regulation, but so far are only “peppered” into EU legislation.
Medtech Insight - May 19, 2026

Multiple Chinese Biotechs Close Back-to-Back Funding Rounds
Since late April, Chinese ventures Best-Link, Starna and Vivacta have closed moderate new financing rounds backed by venture capital and private equity firms within just six months of their last fundraisings.
Scrip - May 19, 2026

US Consumer Health Industry People Moves: Haleon, CeraVe, Nutrabolt, CHPA, More
Haleon’s US marketing chief has Google experience; CHPA Foundation chief adds public affairs post; Nutrabolt adds CPG industry veteran; CeraVe launches campaign with NBA great Anthony; private equity partner has consumer health background; and bio-protein developer Every names first CRO.
HBW Insight - May 19, 2026

Flagship Eyes Long-Term Partnerships, Biopharma Ecosystem Growth In Korea
Flagship Pioneering's APAC head and special advisor share strategies to tap into rising Korean biopharma innovation as the US group seeks new partnerships and to apply its company creation model to the local ecosystem.
Scrip - May 19, 2026

US FDA Acting Foods Program Chief Is Familiar To Dietary Supplement Industry
Agency updates Donal Prater’s biography on its website to indicate he is leading Human Foods Program as acting deputy commissioner for food, the post held by Kyle Diamantas until he was named acting commissioner following May 12 resignation of Martin Makary.
HBW Insight - May 19, 2026

US Personal Care Exports Could Fall $1.9Bn Without USMCA
A PCPC-backed analysis warns that ending or weakening USMCA trade protections could reduce US personal care exports by $1.9bn and disrupt the North American beauty industry’s integrated supply chains.
HBW Insight - May 19, 2026